摘要
目的探索奥沙利铂联合贝伐单抗对结肠癌患者免疫功能的影响,为结肠癌临床联合用药提供参考依据。方法选取2016年3月-2018年2月在内蒙古包头市肿瘤医院接受化疗的114例结肠癌患者为研究对象,按照治疗方式的不同分为对照组和观察组,各57例。对照组采用常规mFOLFOX化疗方案,观察组在对照组的基础上联合贝伐单抗治疗,两组均连续治疗6个月。观察并比较两组患者的近期临床疗效、免疫功能指标、血管内皮生长因子(VEGF)表达水平及不良反应。结果观察组患者临床总有效率显著高于对照组(P<0.05)。与治疗前相比,对照组患者CD4^+、CD8^+水平及CD4^+/CD8^+均无明显变化(P>0.05),而观察组患者CD4^+水平和CD4^+/CD8^+显著升高,CD8^+水平明显降低(P<0.05)。治疗后,观察组患者CD4^+水平和CD4^+/CD8^+显著高于对照组(P<0.05),CD8^+水平低于对照组,但差异无统计学意义(P>0.05)。治疗后,两组患者血清VEGF水平均显著下降(P<0.05),且观察组显著低于对照组(P<0.05)。化疗期间两组患者胃肠道反应、血小板减少、白细胞减少、神经毒性等常见化疗不良反应的发生率比较,差异无统计学意义(χ^2=0.118,P>0.05)。结论贝伐单抗联合奥沙利铂化疗可提高结肠癌患者的临床疗效,改善其免疫抑制状态,促进疾病转归,具有较高的安全性。
Objective To explore the effect of oxaliplatin combined with bevacizumab on immune function of patients with colon cancer,and to provide reference for clinical application.Methods A total of 114 patients with colon cancer who received chemotherapy in Inner Mongolia Baotou Tumor Hospital between March 2016 and February 2018 were selected as the research objects.They were divided into control group and observation group according to the different treatment methods.The patients in control group were treated with conventional FOLFOX regimen.Those in observation group were treated with bevacizumab on the basis of the treatment in control group.Both groups were treated continuously for six months.The short-term clinical efficacy,immune function index,expression level of vascular endothelial growth factor(VEGF)and toxicity and side effects of the two groups were observed and compared.Results The clinical total effective rate of the observation group was significantly higher than that of the control group,and there was a significant difference between the two groups(P<0.05).Compared with before treatment,there were no significant differences in CD4^+,CD8^+and CD4^+/CD8^+in the control group after treatment(P>0.05).But in the observation group,obvious changes were observed including the increase of CD4^+level and CD4^+/CD8^+,and the decrease of CD8^+(P<0.05).Compared with the control group,there were significant differences in CD4^+level and CD4^+/CD8^+in the observation group(P<0.05),but not in CD8^+level(P>0.05).Compared with before treatment,the expression of VEGF in both groups showed a downward trend,and there was statistical difference(P<0.05).In addition,the expression of VEGF in observation group showed a more obvious downward trend than in control group(P<0.05).During the period of chemotherapy,the two groups had different degrees of adverse reactions,such as gastrointestinal reactions,thrombocytopenia,neurotoxicity,leukopenia and other common adverse reactions.There was no significant difference in the number of
作者
刘小雷
王军
李凯
张石在
LIU Xiaolei;WANG Jun;LI Kai;ZHANG Shizai(School of Pharmacy,Inner Mongolia Medical University,Hohhot,Inner Mongolia,010110,China;Department of Pharmacy,Baotou Cancer Hospital,Inner Mongolia 014030;Baotou Cancer Hospital,General Internal Medicine,Baotou 014030,Inner Mongolia;Department of Medicine,Inner Mongolia Erdos Institute of Applied Technology,Erdos,Inner Mongolia,017000,China)
出处
《肿瘤药学》
CAS
2019年第4期586-589,共4页
Anti-Tumor Pharmacy
基金
国家自然科学基金项目（8140066）
关键词
奥沙利铂
贝伐单抗
结肠癌
免疫功能
VEGF
Oxaliplatin
bevacizumab
Colon cancer
immune function
Vascular endothelial growth factor
